As Heart Failure Therapies Improve, High Mortality Persists and Hospice Use Lags
Despite significant breakthroughs in recent years, heart failure (HF) remains a leading cause of death in the US, with no decrease in the rate of mortality. Further, hospice care, which has been demonstrated to greatly benefit patients with advanced HF and their families, continues to be utilized too little and often too late in this population.
Two recently published clinical reviews call this situation a major public health problem.
“Hospice care can ameliorate distress at the end of life for patients with HF, yet it is underused in this population.”Haider J. Warraich, MD, Duke University
“Disease morbidity and mortality remain high, with a five-year survival rate of 25% after hospitalization for HFrEF [HF with reduced ejection fraction],” write the authors of a JAMA article. While the mortality rate for HF decreased by 24% to 33% in earlier decades, they note, it has remained unchanged since the 1990s.
The estimated 6.5 million US adults affected by HF account for approximately one million hospitalizations yearly, they write, with increases in both the incidence and prevalence of HF. “This increase…reflects an aging population, improved survival from myocardial infarction and other cardiovascular diseases, and the increasing prevalence of predisposing risk factors such as diabetes and obesity,” they say.
The article reviewed pertinent literature on HFrEF (in English) through 2020. Included are discussions of HF diagnosis, medical therapies, device treatment, management of comorbidities, cardiac rehabilitation, prognosis, and patient education.
“Once a diagnosis of HFrEF is made, counseling and education for patients and their caregivers is of critical importance,” write the authors. “Estimation of prognosis helps patients and clinicians engage in shared decision making” and “should be re-assessed at every office visit, and especially following major events, such as HF hospitalization.”
Hospice and HF: Underused
“Hospice care can ameliorate distress at the end of life for patients with HF, yet it is underused in this population,” write the authors of an article published in Cardiac Failure Review.2 “HF is an especially burdensome disease both physically and psychosocially. Compared with those with other chronic illnesses, patients with HF have significantly more impairment in quality of life.”
Benefits of hospice for patients with HF include:
- Decreased symptom burden
- Lower rates of hospitalization and 30-day readmission
- Lower risk of ICU admission and invasive procedures at the end of life
- Improved caregiver outcomes and patient/family satisfaction
Barriers to timely hospice referrals include:
- Prognostication challenges in HF
- Medicare’s current 6-month-survival eligibility requirement
- Lack of advance care planning (ACP), which is associated with greater hospice use
The authors urge cardiologists to become comfortable with and proficient in palliative care skills. They also encourage early integration of supportive goals-of-care discussions to help patients with HF develop a “realistic assessment of their expected survival throughout the course of the disease that could assist decision-making related to advance care planning.”
1Murphy, S., Ibrahim, N., & Jauzzi Jr., J. (2020). Heart failure with reduced ejection fraction: A review. JAMA, 324(5): 488-504; DOI: 10.1001/jama.2020.10262.
2Cross, S., & Warraich, H. (2019). Hospice use among patients with heart failure. Cardiac Failure Review, 5(2):93-98; DOI: 10.15420/cfr.2019.2.2.